Halozyme Therapeutics Newsroom

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target

BenzingaJun 27 00:20

Halozyme Therapeutics Analyst Ratings

BenzingaJun 27 00:17

Halozyme Therapeutics Analyst Ratings

BenzingaJun 24 18:10

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target

BenzingaJun 24 18:10

Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $58 From $48, Maintains Overweight Rating

MT NewswiresJun 7 21:23

Halozyme Downgraded at Piper Sandler Despite Guidance Raise

Seeking AlphaJun 7 21:16

Halozyme Therapeutics Analyst Ratings

BenzingaJun 7 17:20

Piper Sandler Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $51

BenzingaJun 7 17:20

Halozyme Therapeutics Analyst Ratings

BenzingaJun 4 18:30

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

BenzingaJun 4 18:30

Halozyme Therapeutics Analyst Ratings

BenzingaMay 22 19:35

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

BenzingaMay 22 19:35

J.P. Morgan Securities: Maintaining the Halozyme Therapeutics (HALO.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $72.00 to $71.00.

Zhitong FinanceMay 9 02:01

Halozyme Therapeutics Analyst Ratings

BenzingaMay 9 02:00

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Lowers Price Target to $71

BenzingaMay 9 02:00

HC Wainwright & Co. : The Halozyme Therapeutics (HALO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $50.00.

Zhitong FinanceMay 8 19:31

Halozyme Therapeutics Analyst Ratings

BenzingaMay 8 19:30

Halozyme Therapeutics Analyst Ratings

BenzingaMay 7 18:15

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

BenzingaMay 7 18:15

Halozyme Therapeutics Analyst Ratings

BenzingaApr 30 18:40